A chief reason that this treatment advanced to clinical trials is that low levels of IL-2 potently suppresses T1D development and reverses recent onset T1D in NOD mice, presumably by enhancing Treg function and/or development (79). The gene discussed is IL2; the disease is type 1 diabetes mellitus.